Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05978167
EARLY_PHASE1

Targeting Drug Memories With Methylphenidate

Sponsor: Icahn School of Medicine at Mount Sinai

View on ClinicalTrials.gov

Summary

This study aims to identify the neural, behavioral, and pharmacological mechanisms promoting diminished expression of drug-related memories in human drug addiction. In this fMRI study with a within-subjects placebo-controlled double-blind cross-over design, oral methylphenidate (20 mg) or placebo will be administered to individuals with cocaine use disorders (CUD) to peak during the retrieval of a drug-cue memory before extinction; in addition to fMRI activations, skin conductance responses (SCR, acquired simultaneously) will serve as the psychophysiological indicators of memory modification. Assessments of interference with the return of drug-cue memories via SCR and craving will be conducted the day following MRI. This pharmocologically-enhanced behavioral approach to decreasing drug memories and craving in iCUD could ultimately be used to develop effective cue-exposure therapies for drug addiction. Procedures include MRI, blood draw, questionnaires and interviews, skin conductance response measures, and behavioral tasks.

Official title: Targeting Neural, Behavioral and Pharmacological Mechanisms of Drug Memories in Drug Addiction With Methylphenidate

Key Details

Gender

All

Age Range

26 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

51

Start Date

2023-07-05

Completion Date

2026-09-03

Last Updated

2025-09-11

Healthy Volunteers

No

Interventions

DRUG

Methylphenidate

Oral administration of 20 mg Methylphenidate

BEHAVIORAL

Memory reconsolidation

Retrieval of drug-cue memories before extinction.

DRUG

Placebo

Matching placebo pill

Locations (1)

Icahn School of Medicine at Mount Sinai

New York, New York, United States